PHARMACEUTICAL BIOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2269936, encodeId=852022699365a, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5df8403416, createdName=ms9000001723067055, createdTime=Wed Jun 18 19:27:53 CST 2025, time=2025-06-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150631, encodeId=5584215063130, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：药理;中药复方 经验分享：SUBMISSION 01 November 2022 Submission Created 01 November 2022 Submission Incomplete 01 November 2022 Manuscript Submitted 01 November 2022 With Journal Administrator 04 November 2022 Submission Returned to Author 05 November 2022 Submission Incomplete 05 November 2022 Manuscript Resubmitted 05 November 2022 With Journal Administrator 20 January 2023 Submission Returned to Author 20 January 2023 Submission Incomplete 20 January 2023 Manuscript Resubmitted 20 January 2023 With Journal Administrator PEER REVIEW 23 November 2022 With Editor 25 December 2022 Out for Review 25 December 2022 Decision Pending 28 December 2022 Revision Required 19 January 2023 Revision Incomplete 19 January 2023 Revised Manuscript Submitted 19 January 2023 With Journal Administrator 21 January 2023 With Editor 22 January 2023 Out for Review 15 February 2023 Decision Pending 12 March 2023 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230731/c6b65f8745254477ac28d88840cb1e0b/9e4ae2e7f9134a7c8800922fb7c19658.jpg, createdBy=94878313457, createdName=ms6000001066593523, createdTime=Mon Jul 31 16:20:12 CST 2023, time=2023-07-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237002, encodeId=7df5223e00210, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：今年6月9号投的稿， 7月底送审 8.28意见就返回来了，小修一下。 9.28返修提交， 11月还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Thu Nov 14 23:22:05 CST 2024, time=2024-11-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198639, encodeId=8f90219863982, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：成分鉴定;中药复方 经验分享：12月9号投的稿，一月底送审的，第一次送审还挺快，一个月左右意见就返回来了，小修一下。然后2.28返修提交，到现在4月中旬了还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Apr 15 17:12:13 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2143739, encodeId=a8732143e395d, content=投稿命中率:25.0 偏重的研究方向：中药复方综述 经验分享：with journal administrater这个状态目前已经半个月了，说是编辑部在初审，合理么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Jun 19 21:40:25 CST 2023, time=2023-06-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2237313, encodeId=2e4e223e31332, content=期刊是一个专注于天然产物和药物生物学研究的权威期刊，尤其在中药和天然药物领域具有较高的影响力。 但是审稿周期较长且编辑效率不高，不太适合急需发表论文的研究人员。 对国人较为友好，近三年国人发文量排名第一。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:16:37 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117061, encodeId=06c3211e06105, content=审稿速度:2.0 偏重的研究方向：天然药物 经验分享：请问一下返修后在哪里提交哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71206511428, createdName=ms8000002023702013, createdTime=Wed Mar 01 15:22:18 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140925, encodeId=b41121409254c, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：中药提取物 经验分享：审稿人一个同意发表，一个建议修回补实验，补完实验修回去，编辑无理由拒稿，就说unsuitable。无语了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Mon Jun 05 17:42:05 CST 2023, time=2023-06-05, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2120664, encodeId=baf12120664b2, content=审稿速度:3.0 经验分享：投稿时，在编辑那里修改了几次格式问题。做复方有液相，外审70天，目前小修中，持续更新后续。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937f5408133, createdName=ms5000000768384636, createdTime=Mon Mar 20 23:40:09 CST 2023, time=2023-03-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190023, encodeId=aa25219002323, content=为什么已经外审了，系统还显示with editor呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fba8367429, createdName=ms7000001909487480, createdTime=Thu Feb 29 09:07:40 CST 2024, time=2024-02-29, status=1, ipAttribution=北京)]

2025-06-18 ms9000001723067055 来自重庆

审稿速度:24.0 | 投稿命中率:50.0
经验分享：非常慢

12 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2269936, encodeId=852022699365a, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5df8403416, createdName=ms9000001723067055, createdTime=Wed Jun 18 19:27:53 CST 2025, time=2025-06-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150631, encodeId=5584215063130, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：药理;中药复方 经验分享：SUBMISSION 01 November 2022 Submission Created 01 November 2022 Submission Incomplete 01 November 2022 Manuscript Submitted 01 November 2022 With Journal Administrator 04 November 2022 Submission Returned to Author 05 November 2022 Submission Incomplete 05 November 2022 Manuscript Resubmitted 05 November 2022 With Journal Administrator 20 January 2023 Submission Returned to Author 20 January 2023 Submission Incomplete 20 January 2023 Manuscript Resubmitted 20 January 2023 With Journal Administrator PEER REVIEW 23 November 2022 With Editor 25 December 2022 Out for Review 25 December 2022 Decision Pending 28 December 2022 Revision Required 19 January 2023 Revision Incomplete 19 January 2023 Revised Manuscript Submitted 19 January 2023 With Journal Administrator 21 January 2023 With Editor 22 January 2023 Out for Review 15 February 2023 Decision Pending 12 March 2023 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230731/c6b65f8745254477ac28d88840cb1e0b/9e4ae2e7f9134a7c8800922fb7c19658.jpg, createdBy=94878313457, createdName=ms6000001066593523, createdTime=Mon Jul 31 16:20:12 CST 2023, time=2023-07-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237002, encodeId=7df5223e00210, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：今年6月9号投的稿， 7月底送审 8.28意见就返回来了，小修一下。 9.28返修提交， 11月还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Thu Nov 14 23:22:05 CST 2024, time=2024-11-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198639, encodeId=8f90219863982, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：成分鉴定;中药复方 经验分享：12月9号投的稿，一月底送审的，第一次送审还挺快，一个月左右意见就返回来了，小修一下。然后2.28返修提交，到现在4月中旬了还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Apr 15 17:12:13 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2143739, encodeId=a8732143e395d, content=投稿命中率:25.0 偏重的研究方向：中药复方综述 经验分享：with journal administrater这个状态目前已经半个月了，说是编辑部在初审，合理么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Jun 19 21:40:25 CST 2023, time=2023-06-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2237313, encodeId=2e4e223e31332, content=期刊是一个专注于天然产物和药物生物学研究的权威期刊，尤其在中药和天然药物领域具有较高的影响力。 但是审稿周期较长且编辑效率不高，不太适合急需发表论文的研究人员。 对国人较为友好，近三年国人发文量排名第一。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:16:37 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117061, encodeId=06c3211e06105, content=审稿速度:2.0 偏重的研究方向：天然药物 经验分享：请问一下返修后在哪里提交哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71206511428, createdName=ms8000002023702013, createdTime=Wed Mar 01 15:22:18 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140925, encodeId=b41121409254c, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：中药提取物 经验分享：审稿人一个同意发表，一个建议修回补实验，补完实验修回去，编辑无理由拒稿，就说unsuitable。无语了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Mon Jun 05 17:42:05 CST 2023, time=2023-06-05, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2120664, encodeId=baf12120664b2, content=审稿速度:3.0 经验分享：投稿时，在编辑那里修改了几次格式问题。做复方有液相，外审70天，目前小修中，持续更新后续。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937f5408133, createdName=ms5000000768384636, createdTime=Mon Mar 20 23:40:09 CST 2023, time=2023-03-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190023, encodeId=aa25219002323, content=为什么已经外审了，系统还显示with editor呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fba8367429, createdName=ms7000001909487480, createdTime=Thu Feb 29 09:07:40 CST 2024, time=2024-02-29, status=1, ipAttribution=北京)]

2023-07-31 ms6000001066593523 来自广东省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：药理;中药复方
经验分享：SUBMISSION
01 November 2022
Submission Created
01 November 2022
Submission Incomplete
01 November 2022
Manuscript Submitted
01 November 2022
With Journal Administrator
04 November 2022
Submission Returned to Author
05 November 2022
Submission Incomplete
05 November 2022
Manuscript Resubmitted
05 November 2022
With Journal Administrator
20 January 2023
Submission Returned to Author
20 January 2023
Submission Incomplete
20 January 2023
Manuscript Resubmitted
20 January 2023
With Journal Administrator
PEER REVIEW
23 November 2022
With Editor
25 December 2022
Out for Review
25 December 2022
Decision Pending
28 December 2022
Revision Required
19 January 2023
Revision Incomplete
19 January 2023
Revised Manuscript Submitted
19 January 2023
With Journal Administrator
21 January 2023
With Editor
22 January 2023
Out for Review
15 February 2023
Decision Pending
12 March 2023
Accepted

1 5 举报

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2269936, encodeId=852022699365a, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5df8403416, createdName=ms9000001723067055, createdTime=Wed Jun 18 19:27:53 CST 2025, time=2025-06-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150631, encodeId=5584215063130, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：药理;中药复方 经验分享：SUBMISSION 01 November 2022 Submission Created 01 November 2022 Submission Incomplete 01 November 2022 Manuscript Submitted 01 November 2022 With Journal Administrator 04 November 2022 Submission Returned to Author 05 November 2022 Submission Incomplete 05 November 2022 Manuscript Resubmitted 05 November 2022 With Journal Administrator 20 January 2023 Submission Returned to Author 20 January 2023 Submission Incomplete 20 January 2023 Manuscript Resubmitted 20 January 2023 With Journal Administrator PEER REVIEW 23 November 2022 With Editor 25 December 2022 Out for Review 25 December 2022 Decision Pending 28 December 2022 Revision Required 19 January 2023 Revision Incomplete 19 January 2023 Revised Manuscript Submitted 19 January 2023 With Journal Administrator 21 January 2023 With Editor 22 January 2023 Out for Review 15 February 2023 Decision Pending 12 March 2023 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230731/c6b65f8745254477ac28d88840cb1e0b/9e4ae2e7f9134a7c8800922fb7c19658.jpg, createdBy=94878313457, createdName=ms6000001066593523, createdTime=Mon Jul 31 16:20:12 CST 2023, time=2023-07-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237002, encodeId=7df5223e00210, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：今年6月9号投的稿， 7月底送审 8.28意见就返回来了，小修一下。 9.28返修提交， 11月还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Thu Nov 14 23:22:05 CST 2024, time=2024-11-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198639, encodeId=8f90219863982, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：成分鉴定;中药复方 经验分享：12月9号投的稿，一月底送审的，第一次送审还挺快，一个月左右意见就返回来了，小修一下。然后2.28返修提交，到现在4月中旬了还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Apr 15 17:12:13 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2143739, encodeId=a8732143e395d, content=投稿命中率:25.0 偏重的研究方向：中药复方综述 经验分享：with journal administrater这个状态目前已经半个月了，说是编辑部在初审，合理么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Jun 19 21:40:25 CST 2023, time=2023-06-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2237313, encodeId=2e4e223e31332, content=期刊是一个专注于天然产物和药物生物学研究的权威期刊，尤其在中药和天然药物领域具有较高的影响力。 但是审稿周期较长且编辑效率不高，不太适合急需发表论文的研究人员。 对国人较为友好，近三年国人发文量排名第一。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:16:37 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117061, encodeId=06c3211e06105, content=审稿速度:2.0 偏重的研究方向：天然药物 经验分享：请问一下返修后在哪里提交哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71206511428, createdName=ms8000002023702013, createdTime=Wed Mar 01 15:22:18 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140925, encodeId=b41121409254c, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：中药提取物 经验分享：审稿人一个同意发表，一个建议修回补实验，补完实验修回去，编辑无理由拒稿，就说unsuitable。无语了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Mon Jun 05 17:42:05 CST 2023, time=2023-06-05, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2120664, encodeId=baf12120664b2, content=审稿速度:3.0 经验分享：投稿时，在编辑那里修改了几次格式问题。做复方有液相，外审70天，目前小修中，持续更新后续。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937f5408133, createdName=ms5000000768384636, createdTime=Mon Mar 20 23:40:09 CST 2023, time=2023-03-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190023, encodeId=aa25219002323, content=为什么已经外审了，系统还显示with editor呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fba8367429, createdName=ms7000001909487480, createdTime=Thu Feb 29 09:07:40 CST 2024, time=2024-02-29, status=1, ipAttribution=北京)]

2024-11-14 ms1000001788822136 来自上海

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：中药
经验分享：今年6月9号投的稿，
7月底送审
8.28意见就返回来了，小修一下。
9.28返修提交，
11月还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了

33 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2269936, encodeId=852022699365a, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5df8403416, createdName=ms9000001723067055, createdTime=Wed Jun 18 19:27:53 CST 2025, time=2025-06-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150631, encodeId=5584215063130, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：药理;中药复方 经验分享：SUBMISSION 01 November 2022 Submission Created 01 November 2022 Submission Incomplete 01 November 2022 Manuscript Submitted 01 November 2022 With Journal Administrator 04 November 2022 Submission Returned to Author 05 November 2022 Submission Incomplete 05 November 2022 Manuscript Resubmitted 05 November 2022 With Journal Administrator 20 January 2023 Submission Returned to Author 20 January 2023 Submission Incomplete 20 January 2023 Manuscript Resubmitted 20 January 2023 With Journal Administrator PEER REVIEW 23 November 2022 With Editor 25 December 2022 Out for Review 25 December 2022 Decision Pending 28 December 2022 Revision Required 19 January 2023 Revision Incomplete 19 January 2023 Revised Manuscript Submitted 19 January 2023 With Journal Administrator 21 January 2023 With Editor 22 January 2023 Out for Review 15 February 2023 Decision Pending 12 March 2023 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230731/c6b65f8745254477ac28d88840cb1e0b/9e4ae2e7f9134a7c8800922fb7c19658.jpg, createdBy=94878313457, createdName=ms6000001066593523, createdTime=Mon Jul 31 16:20:12 CST 2023, time=2023-07-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237002, encodeId=7df5223e00210, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：今年6月9号投的稿， 7月底送审 8.28意见就返回来了，小修一下。 9.28返修提交， 11月还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Thu Nov 14 23:22:05 CST 2024, time=2024-11-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198639, encodeId=8f90219863982, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：成分鉴定;中药复方 经验分享：12月9号投的稿，一月底送审的，第一次送审还挺快，一个月左右意见就返回来了，小修一下。然后2.28返修提交，到现在4月中旬了还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Apr 15 17:12:13 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2143739, encodeId=a8732143e395d, content=投稿命中率:25.0 偏重的研究方向：中药复方综述 经验分享：with journal administrater这个状态目前已经半个月了，说是编辑部在初审，合理么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Jun 19 21:40:25 CST 2023, time=2023-06-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2237313, encodeId=2e4e223e31332, content=期刊是一个专注于天然产物和药物生物学研究的权威期刊，尤其在中药和天然药物领域具有较高的影响力。 但是审稿周期较长且编辑效率不高，不太适合急需发表论文的研究人员。 对国人较为友好，近三年国人发文量排名第一。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:16:37 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117061, encodeId=06c3211e06105, content=审稿速度:2.0 偏重的研究方向：天然药物 经验分享：请问一下返修后在哪里提交哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71206511428, createdName=ms8000002023702013, createdTime=Wed Mar 01 15:22:18 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140925, encodeId=b41121409254c, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：中药提取物 经验分享：审稿人一个同意发表，一个建议修回补实验，补完实验修回去，编辑无理由拒稿，就说unsuitable。无语了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Mon Jun 05 17:42:05 CST 2023, time=2023-06-05, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2120664, encodeId=baf12120664b2, content=审稿速度:3.0 经验分享：投稿时，在编辑那里修改了几次格式问题。做复方有液相，外审70天，目前小修中，持续更新后续。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937f5408133, createdName=ms5000000768384636, createdTime=Mon Mar 20 23:40:09 CST 2023, time=2023-03-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190023, encodeId=aa25219002323, content=为什么已经外审了，系统还显示with editor呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fba8367429, createdName=ms7000001909487480, createdTime=Thu Feb 29 09:07:40 CST 2024, time=2024-02-29, status=1, ipAttribution=北京)]

2024-04-15 ms1000002137683196 来自湖南省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：成分鉴定;中药复方
经验分享：12月9号投的稿，一月底送审的，第一次送审还挺快，一个月左右意见就返回来了，小修一下。然后2.28返修提交，到现在4月中旬了还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了

127 9 举报

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2269936, encodeId=852022699365a, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5df8403416, createdName=ms9000001723067055, createdTime=Wed Jun 18 19:27:53 CST 2025, time=2025-06-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150631, encodeId=5584215063130, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：药理;中药复方 经验分享：SUBMISSION 01 November 2022 Submission Created 01 November 2022 Submission Incomplete 01 November 2022 Manuscript Submitted 01 November 2022 With Journal Administrator 04 November 2022 Submission Returned to Author 05 November 2022 Submission Incomplete 05 November 2022 Manuscript Resubmitted 05 November 2022 With Journal Administrator 20 January 2023 Submission Returned to Author 20 January 2023 Submission Incomplete 20 January 2023 Manuscript Resubmitted 20 January 2023 With Journal Administrator PEER REVIEW 23 November 2022 With Editor 25 December 2022 Out for Review 25 December 2022 Decision Pending 28 December 2022 Revision Required 19 January 2023 Revision Incomplete 19 January 2023 Revised Manuscript Submitted 19 January 2023 With Journal Administrator 21 January 2023 With Editor 22 January 2023 Out for Review 15 February 2023 Decision Pending 12 March 2023 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230731/c6b65f8745254477ac28d88840cb1e0b/9e4ae2e7f9134a7c8800922fb7c19658.jpg, createdBy=94878313457, createdName=ms6000001066593523, createdTime=Mon Jul 31 16:20:12 CST 2023, time=2023-07-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237002, encodeId=7df5223e00210, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：今年6月9号投的稿， 7月底送审 8.28意见就返回来了，小修一下。 9.28返修提交， 11月还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Thu Nov 14 23:22:05 CST 2024, time=2024-11-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198639, encodeId=8f90219863982, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：成分鉴定;中药复方 经验分享：12月9号投的稿，一月底送审的，第一次送审还挺快，一个月左右意见就返回来了，小修一下。然后2.28返修提交，到现在4月中旬了还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Apr 15 17:12:13 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2143739, encodeId=a8732143e395d, content=投稿命中率:25.0 偏重的研究方向：中药复方综述 经验分享：with journal administrater这个状态目前已经半个月了，说是编辑部在初审，合理么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Jun 19 21:40:25 CST 2023, time=2023-06-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2237313, encodeId=2e4e223e31332, content=期刊是一个专注于天然产物和药物生物学研究的权威期刊，尤其在中药和天然药物领域具有较高的影响力。 但是审稿周期较长且编辑效率不高，不太适合急需发表论文的研究人员。 对国人较为友好，近三年国人发文量排名第一。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:16:37 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117061, encodeId=06c3211e06105, content=审稿速度:2.0 偏重的研究方向：天然药物 经验分享：请问一下返修后在哪里提交哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71206511428, createdName=ms8000002023702013, createdTime=Wed Mar 01 15:22:18 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140925, encodeId=b41121409254c, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：中药提取物 经验分享：审稿人一个同意发表，一个建议修回补实验，补完实验修回去，编辑无理由拒稿，就说unsuitable。无语了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Mon Jun 05 17:42:05 CST 2023, time=2023-06-05, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2120664, encodeId=baf12120664b2, content=审稿速度:3.0 经验分享：投稿时，在编辑那里修改了几次格式问题。做复方有液相，外审70天，目前小修中，持续更新后续。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937f5408133, createdName=ms5000000768384636, createdTime=Mon Mar 20 23:40:09 CST 2023, time=2023-03-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190023, encodeId=aa25219002323, content=为什么已经外审了，系统还显示with editor呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fba8367429, createdName=ms7000001909487480, createdTime=Thu Feb 29 09:07:40 CST 2024, time=2024-02-29, status=1, ipAttribution=北京)]

2023-06-19 ms1000002137683196 来自河南省

投稿命中率:25.0
偏重的研究方向：中药复方综述
经验分享：with journal administrater这个状态目前已经半个月了，说是编辑部在初审，合理么

73 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2269936, encodeId=852022699365a, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5df8403416, createdName=ms9000001723067055, createdTime=Wed Jun 18 19:27:53 CST 2025, time=2025-06-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150631, encodeId=5584215063130, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：药理;中药复方 经验分享：SUBMISSION 01 November 2022 Submission Created 01 November 2022 Submission Incomplete 01 November 2022 Manuscript Submitted 01 November 2022 With Journal Administrator 04 November 2022 Submission Returned to Author 05 November 2022 Submission Incomplete 05 November 2022 Manuscript Resubmitted 05 November 2022 With Journal Administrator 20 January 2023 Submission Returned to Author 20 January 2023 Submission Incomplete 20 January 2023 Manuscript Resubmitted 20 January 2023 With Journal Administrator PEER REVIEW 23 November 2022 With Editor 25 December 2022 Out for Review 25 December 2022 Decision Pending 28 December 2022 Revision Required 19 January 2023 Revision Incomplete 19 January 2023 Revised Manuscript Submitted 19 January 2023 With Journal Administrator 21 January 2023 With Editor 22 January 2023 Out for Review 15 February 2023 Decision Pending 12 March 2023 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230731/c6b65f8745254477ac28d88840cb1e0b/9e4ae2e7f9134a7c8800922fb7c19658.jpg, createdBy=94878313457, createdName=ms6000001066593523, createdTime=Mon Jul 31 16:20:12 CST 2023, time=2023-07-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237002, encodeId=7df5223e00210, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：今年6月9号投的稿， 7月底送审 8.28意见就返回来了，小修一下。 9.28返修提交， 11月还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Thu Nov 14 23:22:05 CST 2024, time=2024-11-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198639, encodeId=8f90219863982, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：成分鉴定;中药复方 经验分享：12月9号投的稿，一月底送审的，第一次送审还挺快，一个月左右意见就返回来了，小修一下。然后2.28返修提交，到现在4月中旬了还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Apr 15 17:12:13 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2143739, encodeId=a8732143e395d, content=投稿命中率:25.0 偏重的研究方向：中药复方综述 经验分享：with journal administrater这个状态目前已经半个月了，说是编辑部在初审，合理么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Jun 19 21:40:25 CST 2023, time=2023-06-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2237313, encodeId=2e4e223e31332, content=期刊是一个专注于天然产物和药物生物学研究的权威期刊，尤其在中药和天然药物领域具有较高的影响力。 但是审稿周期较长且编辑效率不高，不太适合急需发表论文的研究人员。 对国人较为友好，近三年国人发文量排名第一。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:16:37 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117061, encodeId=06c3211e06105, content=审稿速度:2.0 偏重的研究方向：天然药物 经验分享：请问一下返修后在哪里提交哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71206511428, createdName=ms8000002023702013, createdTime=Wed Mar 01 15:22:18 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140925, encodeId=b41121409254c, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：中药提取物 经验分享：审稿人一个同意发表，一个建议修回补实验，补完实验修回去，编辑无理由拒稿，就说unsuitable。无语了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Mon Jun 05 17:42:05 CST 2023, time=2023-06-05, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2120664, encodeId=baf12120664b2, content=审稿速度:3.0 经验分享：投稿时，在编辑那里修改了几次格式问题。做复方有液相，外审70天，目前小修中，持续更新后续。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937f5408133, createdName=ms5000000768384636, createdTime=Mon Mar 20 23:40:09 CST 2023, time=2023-03-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190023, encodeId=aa25219002323, content=为什么已经外审了，系统还显示with editor呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fba8367429, createdName=ms7000001909487480, createdTime=Thu Feb 29 09:07:40 CST 2024, time=2024-02-29, status=1, ipAttribution=北京)]

2024-11-16 ms1000001788822136 来自上海

期刊是一个专注于天然产物和药物生物学研究的权威期刊，尤其在中药和天然药物领域具有较高的影响力。
但是审稿周期较长且编辑效率不高，不太适合急需发表论文的研究人员。
对国人较为友好，近三年国人发文量排名第一。

35 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2269936, encodeId=852022699365a, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5df8403416, createdName=ms9000001723067055, createdTime=Wed Jun 18 19:27:53 CST 2025, time=2025-06-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150631, encodeId=5584215063130, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：药理;中药复方 经验分享：SUBMISSION 01 November 2022 Submission Created 01 November 2022 Submission Incomplete 01 November 2022 Manuscript Submitted 01 November 2022 With Journal Administrator 04 November 2022 Submission Returned to Author 05 November 2022 Submission Incomplete 05 November 2022 Manuscript Resubmitted 05 November 2022 With Journal Administrator 20 January 2023 Submission Returned to Author 20 January 2023 Submission Incomplete 20 January 2023 Manuscript Resubmitted 20 January 2023 With Journal Administrator PEER REVIEW 23 November 2022 With Editor 25 December 2022 Out for Review 25 December 2022 Decision Pending 28 December 2022 Revision Required 19 January 2023 Revision Incomplete 19 January 2023 Revised Manuscript Submitted 19 January 2023 With Journal Administrator 21 January 2023 With Editor 22 January 2023 Out for Review 15 February 2023 Decision Pending 12 March 2023 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230731/c6b65f8745254477ac28d88840cb1e0b/9e4ae2e7f9134a7c8800922fb7c19658.jpg, createdBy=94878313457, createdName=ms6000001066593523, createdTime=Mon Jul 31 16:20:12 CST 2023, time=2023-07-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237002, encodeId=7df5223e00210, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：今年6月9号投的稿， 7月底送审 8.28意见就返回来了，小修一下。 9.28返修提交， 11月还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Thu Nov 14 23:22:05 CST 2024, time=2024-11-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198639, encodeId=8f90219863982, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：成分鉴定;中药复方 经验分享：12月9号投的稿，一月底送审的，第一次送审还挺快，一个月左右意见就返回来了，小修一下。然后2.28返修提交，到现在4月中旬了还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Apr 15 17:12:13 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2143739, encodeId=a8732143e395d, content=投稿命中率:25.0 偏重的研究方向：中药复方综述 经验分享：with journal administrater这个状态目前已经半个月了，说是编辑部在初审，合理么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Jun 19 21:40:25 CST 2023, time=2023-06-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2237313, encodeId=2e4e223e31332, content=期刊是一个专注于天然产物和药物生物学研究的权威期刊，尤其在中药和天然药物领域具有较高的影响力。 但是审稿周期较长且编辑效率不高，不太适合急需发表论文的研究人员。 对国人较为友好，近三年国人发文量排名第一。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:16:37 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117061, encodeId=06c3211e06105, content=审稿速度:2.0 偏重的研究方向：天然药物 经验分享：请问一下返修后在哪里提交哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71206511428, createdName=ms8000002023702013, createdTime=Wed Mar 01 15:22:18 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140925, encodeId=b41121409254c, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：中药提取物 经验分享：审稿人一个同意发表，一个建议修回补实验，补完实验修回去，编辑无理由拒稿，就说unsuitable。无语了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Mon Jun 05 17:42:05 CST 2023, time=2023-06-05, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2120664, encodeId=baf12120664b2, content=审稿速度:3.0 经验分享：投稿时，在编辑那里修改了几次格式问题。做复方有液相，外审70天，目前小修中，持续更新后续。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937f5408133, createdName=ms5000000768384636, createdTime=Mon Mar 20 23:40:09 CST 2023, time=2023-03-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190023, encodeId=aa25219002323, content=为什么已经外审了，系统还显示with editor呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fba8367429, createdName=ms7000001909487480, createdTime=Thu Feb 29 09:07:40 CST 2024, time=2024-02-29, status=1, ipAttribution=北京)]

2023-03-01 ms8000002023702013

审稿速度:2.0
偏重的研究方向：天然药物
经验分享：请问一下返修后在哪里提交哇

137 6 举报

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2269936, encodeId=852022699365a, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5df8403416, createdName=ms9000001723067055, createdTime=Wed Jun 18 19:27:53 CST 2025, time=2025-06-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150631, encodeId=5584215063130, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：药理;中药复方 经验分享：SUBMISSION 01 November 2022 Submission Created 01 November 2022 Submission Incomplete 01 November 2022 Manuscript Submitted 01 November 2022 With Journal Administrator 04 November 2022 Submission Returned to Author 05 November 2022 Submission Incomplete 05 November 2022 Manuscript Resubmitted 05 November 2022 With Journal Administrator 20 January 2023 Submission Returned to Author 20 January 2023 Submission Incomplete 20 January 2023 Manuscript Resubmitted 20 January 2023 With Journal Administrator PEER REVIEW 23 November 2022 With Editor 25 December 2022 Out for Review 25 December 2022 Decision Pending 28 December 2022 Revision Required 19 January 2023 Revision Incomplete 19 January 2023 Revised Manuscript Submitted 19 January 2023 With Journal Administrator 21 January 2023 With Editor 22 January 2023 Out for Review 15 February 2023 Decision Pending 12 March 2023 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230731/c6b65f8745254477ac28d88840cb1e0b/9e4ae2e7f9134a7c8800922fb7c19658.jpg, createdBy=94878313457, createdName=ms6000001066593523, createdTime=Mon Jul 31 16:20:12 CST 2023, time=2023-07-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237002, encodeId=7df5223e00210, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：今年6月9号投的稿， 7月底送审 8.28意见就返回来了，小修一下。 9.28返修提交， 11月还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Thu Nov 14 23:22:05 CST 2024, time=2024-11-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198639, encodeId=8f90219863982, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：成分鉴定;中药复方 经验分享：12月9号投的稿，一月底送审的，第一次送审还挺快，一个月左右意见就返回来了，小修一下。然后2.28返修提交，到现在4月中旬了还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Apr 15 17:12:13 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2143739, encodeId=a8732143e395d, content=投稿命中率:25.0 偏重的研究方向：中药复方综述 经验分享：with journal administrater这个状态目前已经半个月了，说是编辑部在初审，合理么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Jun 19 21:40:25 CST 2023, time=2023-06-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2237313, encodeId=2e4e223e31332, content=期刊是一个专注于天然产物和药物生物学研究的权威期刊，尤其在中药和天然药物领域具有较高的影响力。 但是审稿周期较长且编辑效率不高，不太适合急需发表论文的研究人员。 对国人较为友好，近三年国人发文量排名第一。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:16:37 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117061, encodeId=06c3211e06105, content=审稿速度:2.0 偏重的研究方向：天然药物 经验分享：请问一下返修后在哪里提交哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71206511428, createdName=ms8000002023702013, createdTime=Wed Mar 01 15:22:18 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140925, encodeId=b41121409254c, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：中药提取物 经验分享：审稿人一个同意发表，一个建议修回补实验，补完实验修回去，编辑无理由拒稿，就说unsuitable。无语了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Mon Jun 05 17:42:05 CST 2023, time=2023-06-05, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2120664, encodeId=baf12120664b2, content=审稿速度:3.0 经验分享：投稿时，在编辑那里修改了几次格式问题。做复方有液相，外审70天，目前小修中，持续更新后续。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937f5408133, createdName=ms5000000768384636, createdTime=Mon Mar 20 23:40:09 CST 2023, time=2023-03-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190023, encodeId=aa25219002323, content=为什么已经外审了，系统还显示with editor呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fba8367429, createdName=ms7000001909487480, createdTime=Thu Feb 29 09:07:40 CST 2024, time=2024-02-29, status=1, ipAttribution=北京)]

2023-06-05 hongzhongshi 来自福建省

审稿速度:3.0 | 投稿命中率:5.0
偏重的研究方向：中药提取物
经验分享：审稿人一个同意发表，一个建议修回补实验，补完实验修回去，编辑无理由拒稿，就说unsuitable。无语了

148 8 举报

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2269936, encodeId=852022699365a, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5df8403416, createdName=ms9000001723067055, createdTime=Wed Jun 18 19:27:53 CST 2025, time=2025-06-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150631, encodeId=5584215063130, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：药理;中药复方 经验分享：SUBMISSION 01 November 2022 Submission Created 01 November 2022 Submission Incomplete 01 November 2022 Manuscript Submitted 01 November 2022 With Journal Administrator 04 November 2022 Submission Returned to Author 05 November 2022 Submission Incomplete 05 November 2022 Manuscript Resubmitted 05 November 2022 With Journal Administrator 20 January 2023 Submission Returned to Author 20 January 2023 Submission Incomplete 20 January 2023 Manuscript Resubmitted 20 January 2023 With Journal Administrator PEER REVIEW 23 November 2022 With Editor 25 December 2022 Out for Review 25 December 2022 Decision Pending 28 December 2022 Revision Required 19 January 2023 Revision Incomplete 19 January 2023 Revised Manuscript Submitted 19 January 2023 With Journal Administrator 21 January 2023 With Editor 22 January 2023 Out for Review 15 February 2023 Decision Pending 12 March 2023 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230731/c6b65f8745254477ac28d88840cb1e0b/9e4ae2e7f9134a7c8800922fb7c19658.jpg, createdBy=94878313457, createdName=ms6000001066593523, createdTime=Mon Jul 31 16:20:12 CST 2023, time=2023-07-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237002, encodeId=7df5223e00210, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：今年6月9号投的稿， 7月底送审 8.28意见就返回来了，小修一下。 9.28返修提交， 11月还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Thu Nov 14 23:22:05 CST 2024, time=2024-11-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198639, encodeId=8f90219863982, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：成分鉴定;中药复方 经验分享：12月9号投的稿，一月底送审的，第一次送审还挺快，一个月左右意见就返回来了，小修一下。然后2.28返修提交，到现在4月中旬了还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Apr 15 17:12:13 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2143739, encodeId=a8732143e395d, content=投稿命中率:25.0 偏重的研究方向：中药复方综述 经验分享：with journal administrater这个状态目前已经半个月了，说是编辑部在初审，合理么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Jun 19 21:40:25 CST 2023, time=2023-06-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2237313, encodeId=2e4e223e31332, content=期刊是一个专注于天然产物和药物生物学研究的权威期刊，尤其在中药和天然药物领域具有较高的影响力。 但是审稿周期较长且编辑效率不高，不太适合急需发表论文的研究人员。 对国人较为友好，近三年国人发文量排名第一。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:16:37 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117061, encodeId=06c3211e06105, content=审稿速度:2.0 偏重的研究方向：天然药物 经验分享：请问一下返修后在哪里提交哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71206511428, createdName=ms8000002023702013, createdTime=Wed Mar 01 15:22:18 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140925, encodeId=b41121409254c, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：中药提取物 经验分享：审稿人一个同意发表，一个建议修回补实验，补完实验修回去，编辑无理由拒稿，就说unsuitable。无语了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Mon Jun 05 17:42:05 CST 2023, time=2023-06-05, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2120664, encodeId=baf12120664b2, content=审稿速度:3.0 经验分享：投稿时，在编辑那里修改了几次格式问题。做复方有液相，外审70天，目前小修中，持续更新后续。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937f5408133, createdName=ms5000000768384636, createdTime=Mon Mar 20 23:40:09 CST 2023, time=2023-03-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190023, encodeId=aa25219002323, content=为什么已经外审了，系统还显示with editor呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fba8367429, createdName=ms7000001909487480, createdTime=Thu Feb 29 09:07:40 CST 2024, time=2024-02-29, status=1, ipAttribution=北京)]

2023-03-20 ms5000000768384636 来自四川省

审稿速度:3.0
经验分享：投稿时，在编辑那里修改了几次格式问题。做复方有液相，外审70天，目前小修中，持续更新后续。。。。

122 10 举报

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2269936, encodeId=852022699365a, content=审稿速度:24.0 | 投稿命中率:50.0 经验分享：非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5df8403416, createdName=ms9000001723067055, createdTime=Wed Jun 18 19:27:53 CST 2025, time=2025-06-18, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2150631, encodeId=5584215063130, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：药理;中药复方 经验分享：SUBMISSION 01 November 2022 Submission Created 01 November 2022 Submission Incomplete 01 November 2022 Manuscript Submitted 01 November 2022 With Journal Administrator 04 November 2022 Submission Returned to Author 05 November 2022 Submission Incomplete 05 November 2022 Manuscript Resubmitted 05 November 2022 With Journal Administrator 20 January 2023 Submission Returned to Author 20 January 2023 Submission Incomplete 20 January 2023 Manuscript Resubmitted 20 January 2023 With Journal Administrator PEER REVIEW 23 November 2022 With Editor 25 December 2022 Out for Review 25 December 2022 Decision Pending 28 December 2022 Revision Required 19 January 2023 Revision Incomplete 19 January 2023 Revised Manuscript Submitted 19 January 2023 With Journal Administrator 21 January 2023 With Editor 22 January 2023 Out for Review 15 February 2023 Decision Pending 12 March 2023 Accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230731/c6b65f8745254477ac28d88840cb1e0b/9e4ae2e7f9134a7c8800922fb7c19658.jpg, createdBy=94878313457, createdName=ms6000001066593523, createdTime=Mon Jul 31 16:20:12 CST 2023, time=2023-07-31, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237002, encodeId=7df5223e00210, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：中药 经验分享：今年6月9号投的稿， 7月底送审 8.28意见就返回来了，小修一下。 9.28返修提交， 11月还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Thu Nov 14 23:22:05 CST 2024, time=2024-11-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2198639, encodeId=8f90219863982, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：成分鉴定;中药复方 经验分享：12月9号投的稿，一月底送审的，第一次送审还挺快，一个月左右意见就返回来了，小修一下。然后2.28返修提交，到现在4月中旬了还在外审，催了后回信也没有什么有用的消息。得等到什么时候去呀，太慢了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Apr 15 17:12:13 CST 2024, time=2024-04-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2143739, encodeId=a8732143e395d, content=投稿命中率:25.0 偏重的研究方向：中药复方综述 经验分享：with journal administrater这个状态目前已经半个月了，说是编辑部在初审，合理么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2e98540760, createdName=ms1000002137683196, createdTime=Mon Jun 19 21:40:25 CST 2023, time=2023-06-19, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2237313, encodeId=2e4e223e31332, content=期刊是一个专注于天然产物和药物生物学研究的权威期刊，尤其在中药和天然药物领域具有较高的影响力。 但是审稿周期较长且编辑效率不高，不太适合急需发表论文的研究人员。 对国人较为友好，近三年国人发文量排名第一。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:16:37 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2117061, encodeId=06c3211e06105, content=审稿速度:2.0 偏重的研究方向：天然药物 经验分享：请问一下返修后在哪里提交哇, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71206511428, createdName=ms8000002023702013, createdTime=Wed Mar 01 15:22:18 CST 2023, time=2023-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140925, encodeId=b41121409254c, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：中药提取物 经验分享：审稿人一个同意发表，一个建议修回补实验，补完实验修回去，编辑无理由拒稿，就说unsuitable。无语了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Mon Jun 05 17:42:05 CST 2023, time=2023-06-05, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2120664, encodeId=baf12120664b2, content=审稿速度:3.0 经验分享：投稿时，在编辑那里修改了几次格式问题。做复方有液相，外审70天，目前小修中，持续更新后续。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937f5408133, createdName=ms5000000768384636, createdTime=Mon Mar 20 23:40:09 CST 2023, time=2023-03-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190023, encodeId=aa25219002323, content=为什么已经外审了，系统还显示with editor呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fba8367429, createdName=ms7000001909487480, createdTime=Thu Feb 29 09:07:40 CST 2024, time=2024-02-29, status=1, ipAttribution=北京)]

2024-02-29 ms7000001909487480 来自北京

为什么已经外审了，系统还显示with editor呢？

102 1 举报

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务